EGFR and non-small cell lung carcinoma: Among the targeted therapy options, small molecule tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) signaling have shown significant effectiveness in the treatment of NSCLC patients with tumors harboring specific genetic alterations, such as exon 19 deletions and exon 21 L858R point mutations [7].